Digipharms: Healthcare Beyond Barriers

Hello guys,i want to introduce to you platform that deals with health delivery,which is DIGIPHARMS.

DIGIPHARMS value-based healthcare delivery innovative evidence generation and patient empowerment across the healthcare industry.Digipharms Solutions aimed at speeding up the restructuring of much needed healthcare delivery. systems to this value-based approach. The current shortage of the global health infrastructure results in substantial inefficiencies, wasted and least optimal health outcomes in the current health sector, there is a lack of incentives for system health and service providers to focus on mutually beneficial collaboration.

The reimbursement platform will drastically reduce the administrative costs currently associated with the adoption of value-based pricing schemes and potentially revolutionize drug prices and healthcare as we know it today. This Platform will utilize the lucrative features of automated ‘smart contracting’, enabling real time application of flexible pricing models and patient access schemes between healthcare providers, healthcare providers and health information systems and administrative infrastructure of participating institutions will eliminate the need for manual data handling and processing agreements price.The dynamic nature of Reimbursement allows health systems and manufacturers to manage and monitor their budgets more effectively than is possible today. Comprehensive pricing agreements will not result in any additional sources of use or cost to be incurred if a detailed deal is implemented using the current system.

For example, health stakeholders may agree to reimburse 50% of the cost of therapy after 6 months of patient survival and 75% of therapy costs between 6 and 9 months and then 100% of the cost of therapy thereafter while including conditions based on adverse events, disease biomarkers and reduced care as a result of treatment, with minimal additional administrative burden.

Cancer drugs have been the most widely studied in recent years and are driving growth in the 2009 pharmaceutical drug pipeline This poses considerable challenges because these drugs often carry with them high price tags that explain the benefits they get. The cost of patented cancer

Drugs in the US alone have increased 5–10-fold since the turn of the century, with median drug therapy costs around $ 100,000 per year with patients who are typically responsible for 20–30% as joint payments (Kantarijan et al 2014). High prices for innovative therapies that may or may not work may result in patients refusing treatment or choosing a less than optimal treatment plan due to financial difficulties they may face (Zafar et al 2013).

In the United States, the leading payers of United Health, Aetna and Anthem are close to achieving their current target of 50% of total annual health spending through value-based care.

Token Sales

Digipharm (DPH) tokens will be used to pay license fees / access on the Digipharm platform. Access fees will always be determined and fixed in USD value and the number of tokens required will depend on the type of access (producer, patient, payer or provider) combined with the necessary interaction form. The quantity of tokens required for such interactions may change, relative to the market value of the DPH.

DPH token characteristics

• Supply: 100,000,000
• Fixed (ERC-20)
• Ticker code: DPH
• Decimal Places: 18
• Token Price 1.00 USD
• 9.2 DPH token characteristics

DPH token sale Information

Pre — Sale: 15,000,000 DPH
Base Price: 1.00 USD
Pre — Sale Length: 4 Weeks
Pre — Sale Discount: 35%

Main Sale: 50,000,000 DPH
Week 1: 25% Frozen 25 million token
Week 2: 15% Frozen 15 million token
Week 3: 10% Frozen 10 million token
Week 4: 1.00 USD

Links:

WEBSITE: https://www.digipharm.ch/
WHITEPAPER: https://digipharm.ch/docs/DigipharmWP.pdf
TWITTER: https://twitter.com/DigipharmTeam
FACEBOOK: https://www.facebook.com/ digipharmteam /                                              MY BTT:https://bitcointalk.org/index.php?action=profile;u=991175